Crestwood Advisors Group LLC sells 5,053 shares of Gilead Sciences, Inc. (NASDAQ:GILD)

VaselineSeptember 3, 2024

0 4 minutes read

Gilead Sciences logo Crestwood Advisors Group LLC reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 31.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,060 shares of the biopharmaceutical company’s stock after selling 5,053 shares during the period. Crestwood Advisors Group LLC’s holdings in Gilead Sciences were worth $759,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of GILD. Private Wealth Management Group LLC purchased a new stake in Gilead Sciences in the fourth quarter valued at approximately $29,000. CarsonAllaria Wealth Management Ltd. boosted its holdings in Gilead Sciences by 198.3% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 238 shares during the period. Sachetta LLC purchased a new stake in Gilead Sciences in the fourth quarter valued at approximately $30,000. Palisade Asset Management LLC purchased a new stake in Gilead Sciences in the 1st quarter worth approximately $29,000. Finally, Gladius Capital Management LP purchased a new stake in Gilead Sciences in the fourth quarter valued at about $34,000. 83.67% of shares are owned by institutional investors.

Analysts set new price targets

GILD has been the subject of a number of recent research reports. Truist Financial boosted their price objective on shares of Gilead Sciences from $82.00 to $83.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. Robert W. Baird restated a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a report on Thursday, June 20th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Thursday, August 15th. BMO Capital Markets upped their target price on shares of Gilead Sciences from $80.00 to $85.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $70.00 target price on shares of Gilead Sciences in a report on Friday, August 9th. Twelve research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company has a consensus rating of “Moderate Buy” and an average target price of $81.94, according to MarketBeat.

Want more great investment ideas?

See our latest report on Gilead Sciences

Insiders place their bets

In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the transaction, the insider now directly owns 114,979 shares in the company, valued at $8,506,146.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed via this hyperlink. In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the transaction, the insider now directly owns 114,979 shares in the company, valued at $8,506,146.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed via this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $68.63, for a total transaction of $137,260.00. Following the sale, the insider now owns 96,380 shares in the company, valued at $6,614,559.40. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s shares.

Gilead Sciences trading down 0.6%

Shares of GILD opened at $79.00 on Tuesday. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $87.86. The company has a current ratio of 1.14, a quick ratio of 0.95, and a debt-to-equity ratio of 1.18. The company’s 50-day moving average is $73.26 and its 200-day moving average is $70.35. The stock has a market cap of $98.35 billion, a P/E ratio of 219.44, a P/E/G ratio of 2.74 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD – Get Free Report ) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The company had revenue of $6.95 billion for the quarter, compared to analysts’ expectations of $6.64 billion. Research analysts expect that Gilead Sciences, Inc. to post 3.78 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be given a $0.77 dividend. The ex-dividend date is Friday, September 13. This represents an annualized dividend of $3.08 and a yield of 3.90%. Gilead Sciences’ payout ratio is currently 855.56%.

About Gilead Sciences

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops and commercializes medicines in areas of unmet medical need in the United States, Europe and internationally. The company supplies Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, Sunlencs and Atripla for the treatment of HIV/AIDS; Veklury, an intravenous injection for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.